查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1241643

白血病治療的全球市場

Leukemia Therapeutics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

白血病治療的全球市場在2030年前將達到259億美元

在COVID-19後改變的商務環境中，2022年167億美元的白血病治療的全球市場在2030年前將達到259億美元，在2022年到2030年間預計將以年複合成長率5.7％增長。本報告所分析的市場區隔之一的慢性骨髓性白血病年複合成長率將記錄5.4％，到分析期間結束時將達到91億美元。考慮疫情後的復甦，慢性淋巴性白血病領域今後8年的年複合成長率將修正為6.5％。

美國市場估算為45億美元，中國以年複合成長率8.5％增長

美國的白血病治療市場在2022年估算為45億美元。作為世界第2大經濟大國的中國，在2022年到2030年間年複合成長率預計將為8.5％，2030年達到58億美元的市場規模。其他熱門的地區市場有日本和加拿大，在2022年到2030年間預計將各以3％和5.1％的速度成長。在歐洲市場中，德國以年複合成長率3.3％成長。

調查對像企業範例

  • AbbVie, Inc.
  • Altor Bioscience(a NANT Company)
  • Amgen, Inc.
  • Arno Therapeutics, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer Healthcare AG
  • Bellicum Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Emergent BioSolutions, Inc.
  • Erytech Pharma
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Inc.
  • Immune Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Jazz Pharmaceuticals PLC
  • Juno Therapeutics Inc.
  • Meda AB
  • MedImmune LLC
  • Merck & Co., Inc.
  • Midas Pharma GmbH
  • Nippon Shokubai Co., Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Orphan Europe SARL
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Portola Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • XEME Biopharma Inc.
  • Xencor, Inc.
  • ZIOPHARM Oncology, Inc.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP12998

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Leukemia Therapeutics Market to Reach $25.9 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Leukemia Therapeutics estimated at US$16.7 Billion in the year 2022, is projected to reach a revised size of US$25.9 Billion by 2030, growing at aCAGR of 5.7% over the period 2022-2030. Chronic Myeloid Leukemia, one of the segments analyzed in the report, is projected to record 5.4% CAGR and reach US$9.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chronic Lymphocytic Leukemia segment is readjusted to a revised 6.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $4.5 Billion, While China is Forecast to Grow at 8.5% CAGR

The Leukemia Therapeutics market in the U.S. is estimated at US$4.5 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.8 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3% and 5.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Select Competitors (Total 44 Featured) -

  • AbbVie, Inc.
  • Altor Bioscience (a NANT Company)
  • Amgen, Inc.
  • Arno Therapeutics, Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Bayer Healthcare AG
  • Bellicum Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Chugai Pharmaceutical Co., Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Eisai Co., Ltd.
  • Emergent BioSolutions, Inc.
  • Erytech Pharma
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline, Inc.
  • Immune Pharmaceuticals, Inc.
  • Immunomedics, Inc.
  • Jazz Pharmaceuticals PLC
  • Juno Therapeutics Inc.
  • Meda AB
  • MedImmune LLC
  • Merck & Co., Inc.
  • Midas Pharma GmbH
  • Nippon Shokubai Co., Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Orphan Europe SARL
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Portola Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • XEME Biopharma Inc.
  • Xencor, Inc.
  • ZIOPHARM Oncology, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Leukemia Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Leukemia Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Leukemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 4: World 16-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chronic Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for Chronic Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Chronic Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for Chronic Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Acute Lymphocytic Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for Acute Lymphocytic Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Acute Myeloid Leukemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for Acute Myeloid Leukemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • Active Players in United States
    • TABLE 35: USA Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • CANADA
    • Active Players in Canada
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • JAPAN
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • Active Players in Japan
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • CHINA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • Active Players in China
    • TABLE 62: China Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: China 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: China 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: China 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • EUROPE
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Leukemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • FRANCE
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • Active Players in France
    • TABLE 83: France Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: France 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: France 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: France 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • GERMANY
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • Active Players in Germany
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • ITALY
    • Active Players in Italy
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • Active Players in United Kingdom
    • TABLE 110: UK Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • SPAIN
    • Active Players in Spain
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • RUSSIA
    • Active Players in Russia
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • Active Players in Rest of Europe
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Leukemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • Active Players in Australia
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • INDIA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • Active Players in India
    • TABLE 167: India Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 169: India 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 172: India 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 175: India 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • Active Players in South Korea
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • Active Players in Rest of Asia-Pacific
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Leukemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • ARGENTINA
    • Active Players in Argentina
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • BRAZIL
    • Active Players in Brazil
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • MEXICO
    • Active Players in Mexico
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • Active Players in Rest of Latin America
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Leukemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Leukemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • IRAN
    • Active Players in Iran
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • ISRAEL
    • Active Players in Israel
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • Active Players in Saudi Arabia
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • Active Players in United Arab Emirates
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • Active Players in Rest of Middle East
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030
  • AFRICA
    • Leukemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • Active Players in Africa
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Leukemia Therapeutics by Type of Leukemia - Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Leukemia Therapeutics by Type of Leukemia - Percentage Breakdown of Value Sales for Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia and Acute Myeloid Leukemia for the Years 2014, 2023 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Leukemia Therapeutics by Molecule Type - Small Molecules and Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Leukemia Therapeutics by Molecule Type - Percentage Breakdown of Value Sales for Small Molecules and Biologics for the Years 2014, 2023 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Leukemia Therapeutics by Treatment Type - Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Leukemia Therapeutics by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy, Immunotherapy and Other Treatment Types for the Years 2014, 2023 & 2030

IV. COMPETITION